Skip to main content

Single Dose of mRNA-1345 Vaccine Safe, Effective Against RSV in Seniors

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 14, 2023.

By Elana Gotkine HealthDay Reporter

THURSDAY, Dec. 14, 2023 -- A single dose of mRNA-1345 vaccine is safe and results in lower incidence of respiratory syncytial virus (RSV)-associated disease in older patients, according to a study published in the Dec. 14 issue of the New England Journal of Medicine.

Eleanor Wilson, M.D., from Moderna in Cambridge, Massachusetts, and colleagues conducted a randomized, phase 2 to 3 trial in which adults aged 60 years of age or older were randomly assigned to receive one dose of mRNA-1345 (50 μg; 17,793 participants) or placebo (17,748 participants).

Participants were followed for a median of 112 days. The researchers found that vaccine efficacy was 83.7 and 82.4 percent against RSV-associated lower respiratory tract disease with at least two signs or symptoms and against the disease with at least three signs or symptoms, respectively. Vaccine efficacy against RSV-associated acute respiratory disease was 68.4 percent. Protection was seen against RSV subtypes A and B and was mainly consistent across subgroups defined according to age and coexisting conditions. Compared with those in the placebo group, participants in the mRNA-1345 group had a higher incidence of solicited local adverse reactions (58.7 versus 16.2 percent) and of systemic adverse reactions (47.7 versus 32.9 percent); most reactions were mild-to-moderate and transient. Overall, 2.8 percent of each trial group had serious adverse events.

"This phase 2 to 3 efficacy trial showed that a single 50-μg dose of the mRNA-1345 vaccine in adults 60 years of age or older was efficacious against a spectrum of RSV-confirmed respiratory disease," the authors write

The study was funded by Moderna, the manufacturer of the mRNA-1345 vaccine.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted December 2023

Read this next

No Decline in Cardiovascular Events Seen With COVID-19 Vaccine After Acute Coronary Syndromes

MONDAY, June 3, 2024 -- Patients who have received at least one COVID-19 vaccine dose after acute coronary syndromes do not have a reduced risk for cardiovascular events...

At-School Vaccination Boosts HPV Vaccination Coverage

THURSDAY, May 30, 2024 -- At-school vaccination may be a useful tool to increase human papillomavirus (HPV) vaccination coverage among adolescents, according to a study published...

Preparedness for HPAI A(H5N1) Virus Varies Across Jurisdictions

TUESDAY, May 21, 2024 -- Variation is seen in preparedness and response to highly pathogenic avian influenza (HPAI) A(H5N1) viruses, according to a research letter published...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.